Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 10/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 10/20 | 0.79 |
| ▸ | ITGB8 | P26012 | 10/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106842 | 1.00 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL7318506 | 1.00 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6108645 | 0.97 | ITGAV (0.95) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6107101 | 0.97 | ITGAV (0.95) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6107105 | 0.97 | ITGAV (0.95) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6112430 | 0.94 | ITGAV (0.89) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6106306 | 0.94 | ITGAV (0.89) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6111953 | 0.94 | ITGAV (0.89) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL7437065 | 0.91 | ITGAV (0.84) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL7443148 | 0.91 | ITGAV (0.84) | ITGAVITGB3ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349548-A4 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO INC (US) | 2004-06-02 | — | — | EP | claimed |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | HARTMAN GEORGE D (US) | 2004-03-18 | — | — | US | claimed |
| EP-1349548-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | Merck & Co., Inc. (US) | 2003-10-08 | — | — | EP | claimed |
| US-6444680-B1 | FOR USE IN THERAPY OR PROPHYLAXIS OF OSTEOPOROSIS AND FOR THE TREATMENT OF VASCULAR RESTENOSIS, MACULAR DEGENERATION, DIABETIC RETINOPATHY, ATHEROSCLEROSIS, INFLAMMATORY ARTHRITIS, CANCER, AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-09-03 | — | — | US | claimed |
| WO-2002053099-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO., INC. (US) | 2002-07-11 | — | — | WO | claimed |
| US-20020065291-A1 | Amine salts of an integrin receptor antagonist | MERCK & CO., INC. | 2002-05-30 | — | — | US | claimed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | claimed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | claimed |
| US-20220370545-A1 | INTEGRIN RECEPTOR ALPHA V BETA 3 AND ITS LIGAND INVOLVED IN CHRONIC ITCH | NORTH CAROLINA STATE UNIVERSITY | 2022-11-24 | — | — | US | disclosed |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2018-04-26 | — | — | US | disclosed |
| US-6764842-B2 | Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates | MERCK & CO., INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1349548-A4 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO INC (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | HARTMAN GEORGE D (US) | 2004-03-18 | — | — | US | disclosed |
| US-6444680-B1 | FOR USE IN THERAPY OR PROPHYLAXIS OF OSTEOPOROSIS AND FOR THE TREATMENT OF VASCULAR RESTENOSIS, MACULAR DEGENERATION, DIABETIC RETINOPATHY, ATHEROSCLEROSIS, INFLAMMATORY ARTHRITIS, CANCER, AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-09-03 | — | — | US | disclosed |
| WO-2002053099-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO., INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020065291-A1 | Amine salts of an integrin receptor antagonist | MERCK & CO., INC. | 2002-05-30 | — | — | US | disclosed |
| US-20020065291-A1 | Amine salts of an integrin receptor antagonist | MERCK & CO., INC. | 2002-05-30 | — | — | US | disclosed |
| US-20020040030-A1 | Alpha V integrin receptor antagonists | COLEMAN PAUL J (US) | 2002-04-04 | — | — | US | disclosed |
| WO-2002022616-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040030-A1 | Alpha V integrin receptor antagonists | VCAM1, ITGAV, ITGB1 | ITGAV 2/4885ITGB3 5/4885ITGB6 19/4885 |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | ITGAM, ITGAL, ITGB1 | ITGAV 9/4885ITGB3 8/4885ITGB6 27/4885 |
| US-20020065291-A1 | Amine salts of an integrin receptor antagonist | ITGB3, ADGRE5, ITGA5 | ITGAV 14/4885ITGB3 1/4885ITGB6 9/4885 |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | ITGAM, ITGB1, ITGB2 | ITGAV 5/4885ITGB3 9/4885ITGB6 24/4885 |
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | ITGAV 1/4885ITGB3 2/4885ITGB6 9/4885 |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | ITGB3, ITGB5, ITGB2 | ITGAV 11/4885ITGB3 1/4885ITGB6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.